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NATIONAL INITIATIVES FOR THE SUPPORT OF BIOTECHNOLOGY
A comparative assessment of the United States. Japan. and
the Member States of the European Community
SUMMARY
Based on published reports and statistics. this paper describes national
efforts for the promotion of biotechnology ; with particular reference to
public sector R & D expenditure. The multi-disciplinary nature of
biotechnology and its many sectors of application give rise to major
problems of definition and of international comparability. Figures given
are therefore tentative. and wide ranges reflect definitions varying from
very narrow. to those substantially overlapping agricultural and medical
research. With thes~ caveats. the following figures are deduced for
publicly supported R & D in biotechnology and related areas. at
approximately 1982/83 :
S. : at least '$ 200 m. p. a. ; up to  550 m. p. a. on "broad
basis
" ;
Japan at least $ 50 m. p.a. ;
: 146 m. Ecu on narrow basis. up to 355 m. Ecu on broad basis ($ 156
m. -  380 m. p.
------------ 3-
NATIONAL INITIATIVES FOR THE SUPPORT OF BIOTECHNOLOGY
(A comparative assessment of the United States. Japan and the Member
States of the European Community)
The rise of interest in the significance of biotechnology was marked by a
series of national reports. rising to a peak in 1981 when more than 10 were
published (see list attached. page 5).
Many of these reports recommended the establishment of special agencies. ad
hoc committees. interminisnterial groups etc., and the allocation or
increase of funds for research and development activities in biotechnology.
Through these administrative actions and the funding of "mobilisation
programmes , significant additional research and related activity in
biotechnology is now being implemented. throughout the countries of the
European Community and in most other developed industrial countries.
This annex provides some statistics on the scale of these expenditures
but in appraising the relative strengths of different countries in the
field. the problem of defining biotechnology has to be borne in mind. Since
different countries include different activities in their understanding of
the term. obj ective comparisons are difficult. Fuller details are given in
the document XII-37/83 "Plan by Objective : Biotechnology . One of the
papers prepared in support of the Community s R & D Framework Programme
(1983-87) . This paper includes some more recently published and up-to-date
figures ; but there remain major problems of interpretation. The resulting
estimates of expenditure on biotechnology, or lib iotechnology-relevant" R &
D. are therefore given as indicative ranges.
1.1.
MAJOR NON-COMMUNITY COUNTRIES
The United States of America
1.  Federal Support
The main federal support for activities related to biotechnology is
channelled through two sources : the  National Science Foundation
(NSF). which is the principal federal agency for the support of
basic research across all fields of science, and the National
available, in English or French, from the Commission
Directorate-General XII, for Science, Research and Development.Institutes of Health (NIH), which are responsible for basic research
in medicine and health care, and are also .responsible for the
registration of federally funded research work on recombinant DNA.
The U. S. Department of Agriculture is also funding basic research
related to agriculture, including projects and techniques which may
be described as biotechnology ; similarly the Department of Energy I s
studies of biomass-based energy sources involve basic biology and
biotechnology.
In fiscal year 1980, the NIH supported 717 basic research projects
involving recombinant DNA at a cost of $ 91. 5 million. At the
request of the OTA (see below), the NIH recently estimated what
proportion of their budget ($ 3. 74 bn. estimated outlays for fiscal
year 1983 ; $ 3. 44 bn FY 1982) might be classified as
biotechnology" : for FY 1982, approximately $ 380 m., versus $ 170
m. in 1980 ; plus $ 20 m. for equipment in the "biotechnology
resources program . The $ 380 m. figure is "a maximum
approximation. .. the total costs of the awards not limited to the
subject of the search" the 1980 rDNA figure of  90 m. might be
taken as a minimum.
Biotechnology-relevant" research supported by the NSF in fiscal
***
1980 amounted to  66 m. according to Zaborsky
Special report, "R.~ D Spending on Biotechnology in the U. S. , from the
Science, Technology and Energy Section of the Commission s Washington
office.
***
Paper by Oscar Zaborsky. of U. S. National Science Foundation, at
Eastbourne, April 1981 : Second European Congress of Biotechnology.- 5-
KEY REPORTS IN BIOTECHNOLOGY
- 1974
1976
1976
W. Germany
Japan
1977 Commission of
the E.
1978 Europe
1979 France
1979 France
Jan. Germany
Mar.
May Belgium
Sept. Canada
Feb. Canada
Feb. France
Mar.
Apr.
Apr.
May Netherlands
May Ireland
Sept-81
Sept. Spain
Oct. Japan
Nov. UNIDO
Nov. Australia
Dec. U. S. S. R.
Apr. Netherlands
Sept. OECD
Dec. France
Dec. Italy
Jan.
Summer Ireland
1983
Autumn
1983
DECHEMA, for BMFT : Biot~chnologie
MITSUI : Present and Future On Enzyme Technology
EMERY, for Science Research Council: Biochemical
Engineering.
DG XII: Possible Action of the European Communities
for the optimal exploitation of the fundamentals
of the new biology in applied research.
DECHEMA organise first European Congress of Biotechnology,
Inter1aken, Switzerland; European Federation 
Biotechnology founded.
F .GROS, F .JACOB, P . ROYER : Sciences de 1a vie et societe
pour 1e President de 1a Republique.
J. de ROSNAY : Biotechnologies et Bio- Industrie.
BMFT Leistungsp1an 04 : Biotechno1ogie
SPINKS REPORT" Biotechnology : report of a joint Working
Party (ACARD ,ABRC , Royal Society).
SPPS : Developpements en matiere de biotechnologies.
MILLER et a1 : Biotechnology in Canada.
Report to Minister for Science and Technology:
Biotechnology: a development plan for Canada.
J .C. PELISSOLO : la Biotechno1ogie, demain ?
Govt.White Paper: Biotechnology (response to SPINKS).
ZABORSKY : Biotechnology at the National Science
Foundation.
Office of Technology Assessment : Impacts of Applied
Genetics : Hic ro-Organisms, Plant s and Animals.
STT : Biotechnology: a Dutch perspective.
NBST : Biotechnology Trends.
Office of Technology Assessment: Proj ect Proposal for a
Comparative Assessment of Biotechnology.
La ingenieria genetica en la biotechnologia (Centro para e1
Desarrollo technologico Industrial, Ministerio de Industria
y Energia).
Report : Heading toward new Research and Development, by
the Study Association for the Foundation of a Long-Term
Plan for the Development of Industrial Technology.
The Establishment of an International Centre for Genetic
Engineering and Biotechnology (ICGEB) repdrt of a group of
experts (proposal).
Biotechnology R&D : the application of DNA techniques in
research and opportunities for biotechnology in Australia
(Commonwealth Scientific and Industrial Research
Organization) .
Speech by Academician OVCHINNIKOV at. the Annual General
Meeting of the Soviet Academy of Sciences.
Programmacommissie Biotechno1ogie : Innovatieprogramma
Biotechnologie (Chairman: Prof. R. A. SCHILPEROORT).
International Trends & Perspectives in Biotechnology: A
State of the Art Report by A. BULL, G. HOLT and M.
LILLY.
Programme Mobi1isateur of the Mission Biotechnologie.
ENI group: 1e Prospettive de11' Ingegneria Genetica.
FAST report, recommending Community Strategy for Eur.
Biotechnology.
NBST : Maj or national policy document on
biotechnology.
OTA : Comparative Assessment of the Commer. dev. of
Biotechnology.- 6-
The Office of Technology Assessment study "Impacts of Applied Genetics
Micro-organisms, Plants and Animals" (1981) gives details of federal
support for proj ects on plant molecular genetics and other biological
topics of agricultural significance. Their figures include some NSF
programmes in plant research; the other main channel is the U. S.
Department of Agriculture (USDA). USDA I S Competitive Grants Programme
(1982: $ 16. 5 m. ) supports new research directions in plant biology. But
as with the NIH budget, the biotechnology-relevant research is overshadowed
by the total budget of the Agricultural Research Service ($ 458 m. proposed
for fiscal 1984).
The ARS budget itself forms only part of the Dept. of Agriculture s total R
& D spending ($ 830 m. estimated outlays in FY 1983), and including state
programmes the total is over $ 1. 5 bn. a year.
The biotechnology element was estimated as $ 40 m. out of $ 426 m. in FY
1982, and the proportion is rising. In addition, federal ($ 15 m. ). state
($ 15 m. ) and private  (i  5 m. ) funding supports the State Agricultural
Experimental Stations I work in biotechnology research.
The structure and control of U. S. agricultural research are the subject of
intense current debate . A factor in this debate is the relevance of the
new biotechnology to agriculture, which has been emphasised by long-term
studies, particularly
(i) "The Impending Revolution in World Agriculture , Futures Group
(1982), and
(ii) An Assessment of the Global Potential of Genetic Engineering in the
agri-business Sector, Chicago Group (1981).
The latter points out that the market for agricultural products is "close
to ten times the size of the market for all pharmaceutical health care
products in the U. S. alone , and consequently predicts that the market for
neW genetically engineered products in agriculture could ultimately
outstrip the medical market by tens of billions of dollars.
Emerging biotechnologies in agriculture : issues and policies
Progress report November 1982, Division of Agriculture Committee on
Biotechnology, National Association of State Universities and
Land-Grant Colleges.
Science for Agriculture , report of a workshop (June 1982) on
critical issues in American agriculture research, jointly sponsored
by the Rockefeller Foundation .and the Office of Science and
Technology Policy ; pub. by Rockefeller Foundation, October 1982.- 7-
Combining the figures mentioned suggests U. S. federal expenditure
least $ 200 m. p. a. in areas directly relevant to biotechnology;
equal or greater relevance to the country s strategic capability,
of at
but of
are the
much larger sums referred to in health and agricultural research. In both
these fields, reasonable judgements seem to indicate that some 10 % may be
viewed as "biotechnology-relevant ; hence one can build up the following
estimate on this broader basis
NIH : 10 % of $3. 7 bn/NIH estimate =
Biotechnology resource Program
NSF :
USDA:
(1980, careful estimate)
10 % .of ARS $ 426 m. (1982) =
380
(50
10-
550
+ biotechnology elements of State
Agricultural Experiment Stations
federal. 50 % State)
+ Dept. of Energy and other agencies
The U. S. Government is examining its strategy in the field of
biotechnology. The Office of Technology Assessment is responsible
means of a 2 year study (1981-83 ; to appear in autumn ' 83) will
and by
consider
issues of Government policy. funding and regulatory requirements in this
field, university/industry relationships and relevant features of the
educational system, industry characteristics and patent law. The study will
be comparative and extend therefore to Japan, West Germany, Great Britain,
Canada, France, Switzerland and the USSR.
1. 1. 2.  The role of industry
It is clear that biotechnology research and development is being
substantially funded in the U. S. Industrial funding is probably
several times that of federal expenditure (narrow definition). which
is concentrated at the fundamental end of the research spectrum.
Venture capital activity on the other hand is aiming for payback
(either revenue , or capital gain) in the short and medium term,
particularly in the bie-medical and pharmaceutical fields ; but
larger companies (particularly the major oil, chemical and
pharmaceutical groups) are investing in longer term potential, with
the expectation that research breakthroughs during the next ten
years will lead to commercial products in the years beyond.1.2.  Japan
1.  National Support for Biotechnology R & D
Government support for biotechnology dates from the beginning of the
1970s. The Science and Technology Agency initiated the neW
government biotechnology programmes by establishing a Committee for
the Promotion of the Life Sciences in 1973. Rogers describes how
Since then, the scale of Government support for biotechnology R & D
has steadily increased. Support in 1981 for Life Science in general
is estimated at a minimum of Yen 50. 000 million  (i  210 m.
). 
and
if one considers only the more restricted areas which are currently
referred to as biotechnology the support was of the order of Yen
600 million in 1981 (i. e. approximately  $ 24 million). Government
financial support has received fresh impetus in the last year with
the announcement of the Ministry of International Trade and
Industry s (MITI) biotechnology national projects. These new
projects are the Biomass Development Project concerned with alcohol
production (7 years from 1980-tota1 budget Yen 12, 300 million: $ 52
) and the next Generation Industries national proj ect which has
three biotechnology themes ( 10 years from 1981 - total budget in the
biotechnology sector is in excess of Yen 30, 000 million:  $ 127
m. )
" .
Adding the above three elements: $ 24 m, plus $ 52 m/7 = $ 7 m.
a. ,plus $ 127/10 = $ 13 m. p. a., gives  an estimate of $ 44 m.
; but in the absence of details of the $ 24 m. figure quoted.
this is  probably a significant under-estimate , omitting in
particular any reference to the funding through the Ministries of
Agriculture, Health and Education, all of which give some support
for Biotechnology research, and the "coordination funds" from the
Council for Science and Technology.
A more recent report
***
quotes 7, 471 Y for government expenditure
on biotechnology R & D in 1982, and 7.906 m. Y ($ 33. 2 m. ) budgetted
for 1983. apparently including all ministries and agencies ; if this
omits the national projects cited, the total must be well over $ 50
m. p.a. for 1983.
Rogers, M.D. "The Role of the Japanese Government in Biotechnology
Research and Development , Chemistry and Industry, 7 Aug. 1982.
Y 236 /$, April ' 83.
McGraw Hill "Biotechnology Newswatch" , 21 March 1983 
: "
Japan f s R &
D biobudget jumps 5. 8 %"
***
(2)- 9-
Diagram 1 The Main Organisations Involved in Japanese
Government Support for
Biotechnology
Cabinet
Prime Minister
Office
R&D Policy
R&D Execution
Science Council
of Japan
Council for Science
& Technology
Science & Technology
Agency
Institute of Physical
& Chemical Research
Ministry of Intern.
Trade & Industry
Industrial
Technology
Fermentation
Research Inst.
Ministry .of Agriculture
Forestry & Fisheries
Agricu1ture,Forestry
& Fisheries Research
Council
Various Research
Institutes
Ministry of Healt
& Welfare
Various Research
Institutes
Ministry of
Education
University
Research
Source : Rogers. op. cit.
A detailed qualitative description of government support for biotechnology
R&D is given in the JETRO report ; the following summary is based on
both reports, the figures being from Rogers.
Japan External Trade Organization (JETRO) : The Japan Industrial and
Technological Bulletin. Special Issue 14. 1982 : Research on
Biotechnology in Japan.~ 10-
The Council for Science and Technology (CST). chaired by the Prime
Minister and including the President .of the Science Council of Japan
(the top scientific body), .establishes general science policy and
passes recommendations to the various ministries for executive
action. It is responsible for overall coordination, and in
biotechnology JETRO mentions seven biotechnology-related research
themes being promoted in 1982 from CST's "Special Coordination
Funds" : no figures available.
The Science and Techr.ology Agency (STA) has two roles
a) policy and inter-ministry coordination
b) its own R & D programmes. including biotechnology.
It has to overcOme inter-ministerial rivalries, and Rogers considers
it "fairly effective in the field of biotechnology, not least
because STA was involved from the beginning with its own programmes
and because it has taken a central role in the setting of rDNA
regulations . It attempts to  establish national science and
technology strategy and to help coordinate departmental efforts.
The STA  Life Sciences Programme is directed by the  Committee for the
Promotion of Life Science , the 15 proj ectsmanaged and controll~d
through the (nominally) independent Institute of Physical and
Chemical Research (IIRIKEN"). Expenditure on the proj ects WaS Y 640
m. in 1981 (~ 2.7 tn. ). The essential distinction between the STA
biotechnology projects and those of MITI (see below) is that the
former concentrate on basic medical aspects and longer-term advanced
bioreactors, whereas those of MITI are mainly concerned with fine
chemicals, alternative routes to petrochemicals, enzyme technology.
and general applications of biotechnology to the chemical industry.
A feature of interest at RIKEN is its role in coordinating national
policy for culture collections, and the establishment of a Life
Science Information department to develop "NISLO" : National
Information System for Laboratory Organisms. (cf. the Community
Task Force for Biotechnology Information, under the Committee for
Information and Documentation in Science and Technology).11 
The  Ministry of International Trade and Industry (MITI) inaugurated
a maj or national programme on 1st October 1981, "The Next Generation
Industrial Foundation Technology Development System . Of this
10-year, Y 104 bn. programme, some Y 30 bn ($ 127m) is for
biotechnology. MITt has since (June ' 82) established a lIBioindustry
Office designed to draft "comprehensive measures for smoothly
cultivating the new industrial field known as the bioindustry , and
plans and measures to promote domestic biotechnology research and
international cooperation in the development of the industry, while
projecting the industry s future visio~'
The programme of research is being implemented partly through the
ministry s own institutes - particularly the  Fermentation Research
Institute - and partly through the private sector in a grouping of
14 firms (predominantly chemical majors) known as the "Research
Association for Biotechnologyll or "Biotechnology Forum
MITI has also launched the  Biomass DevelopmentProj ect already
referred to, establishing (May 1980) within its Basic Industries
Bureau a "Biomass Policy Office to establish the feasibility of
Biomass utilisation in Japan and the most promising lines for
development. Projects are being executed through the 22 member
companies of the "Biomass Research Association (petroleum, chemical
and fermentation)" (Rogers) or "Research Association for Petroleum
Alternatives Development (RAPAD)" (JETRO).
The Ministry of Agriculture, Forestry and Fisheries is conducting
research through its institutes, including rDNA work, "with the aim
of developing innovative technologies conducing to the stabilization
of food supplies and sophistication of agriculture" (JETRO). The
JETRO report describes three themes : green energy, biomass
conversion (particularly waste utilisation), and genetics. Rogers
gives figures for the second of these : Y 300 m. (~ 1. 3 m. ) in 1982.
Noteworthy is the fact that  over 30 % of Japanese government R & D
is spent on Agriculture (1979)
The Ministry of Health and Welfare is engaged in research On
biotechnology, including rDNA, lIwith the specific aim of applying
related technologies to health preservation and medical treatments
(JETRO), through the National Institute of Health and other
institutes. No details.
Economist. 6 Nov. 1982 : "Inte.rnational R & D spending.- 12-
The  Ministry of Education supports fundamental research in the
university research organisations. and extends "Science and
Technology Research Subsidies" to proj ects advancing the progress of
science and technology in Japan. No details.
2.  Industrial activity
Japan is particularly strong in fermentation technology, for
historical reasons going back a century (government reVenues from
the  sake industry) ; public initiatives reinforced this pre-eminence.
in the post-war period. Gregory claims that "By the 1970s, Japan
fermentation industry had a 10-year lead over others in the
world.... In 1979, 7 of the 11 new antibiotics introduced across the
world came from Japanese laboratories and in 1980 the Japanese
industry ranked second only to the US in producing new drugs . The
pharmaceutical firms are among the leaders in perfecting
third-generation cephalosporins. in spite of R & D budgets small in
comparison to those of the U. S. and European firms. (Takeda. the
largest. $ 100 m. in 19.81 ; cf. Hoechst $ 270 m. ; Merck $ 275 m. 
Eli Lilly $ 235 m. ; Hoffmann-La Roche, $ 400 m. ; Johnson & Johnson
$ 161 m.
But Pharmaceuticals may be less important than the food sector as
leading edge in biotechnology (the reVerse of the U. S. position).
Japan s fermentation expertise originated in the food sector, and is
reflected in dominance of world production of amino acids (which may
be used as food additives for flavouring, or in order to improve the
amino-acid profile of protein foods or feedstuffs). This is a $ 1.
billion market worldwide. Ajinomoto, one of the major food
companies, has developed (and is patenting) genetic engineering
methods for amino acid production. which it claims will double
existing yields. A major dairy firm, Showa Brand Milk Products is
building a ~ 20 m. biotechnology laboratory for completion in March
1983 and later expansion; it started work on biotechnology research
only in January 1981, concentrating on food, enzymes and
fermentation. Future plans include pharmaceuticals.
New Scientist, 29 July 1982 
: "
Biotechnology-Japan' s growth industry
by Gene Gregory, professor business studies at Sophia University, Tokyo.- 13-
Japanese firms (Kanegafuchi, Dianippon) originated the development
work on hydrocarbon-based single-cell prot~in production, although
consumer acceptance problems subsequently delayed development. The
technology was subsequently licensed to European Producers such as
Liquichima (Italy) and Roniprot (Rumania).
As part of the strategy of establishing independent technology
Japanese pharmaceutical firms are seeking to buy their way into
interferon production and the genetic engineering technology which
provides one route into it. Green Cross has an agreement with
Collaborative Genetics for research on a yeast based process for
interferon, and another with Genex for research on albumin
production.
In October 1981, it concluded an agreement with Biogen for marketing
the latter s hepatitis B vaccine. Takeda, Japan s largest drug
company has signed a contract with Hoffman-La Roche for joint
research and production of interferon in Japan, using the latter l s
genetic engineering technology. Other companies mentioned as buying
foreign genetic engineering technology are Kyowa Hakko (for
interferon) and Mitsubishi. The most signifi~ant j oint venture
involving licensing agreements is Takeda s alliance with the
American firm Abbott. Takeda-Abbott Products have manufacture and
marketing rights for all neW American drug patents obtained by
Takeda, who also have j oint ventures involving Bayer (West Germany)
and Roussel Uclaf (France).
Gregory suggests that a conservative estimate of current output from
industrial microbiology in Japan is Y 11-12 trillion (S50 bn. ) in
food, pharmaceuticals and refined metals, i. e. some 5 % of GNP ; but
recent Japanese sources quote only Y 4tn for 1979, presumably using
a narrower definition. MITI I S Agency for Industrial Science and
Technology forecasts a Japanese domestic market of Y 7 tn. by year
2000 (~ 30 bn.
A detailed survey of research on biotechnology by Japanese
corporations was conducted by MITIin August 1982, and the results
are reported in full by JETRO (op.cit. ). They show (see table below)
rapidly rising industry research expenditure on biotechnology over
the last three years : the 1982 total is Y 47.8 bn. (g 203 m.- 14-
Table 1.
Total Research Expenditures and Biotechnology Research Expenditures
Unit Y 1 million
Medical Drug Chemical Fiscal Total Biotechnology Total Biotechnology
Year research research research research expendit. expenditures expendit. expenditures
Textile, Pa er & Pul Total Biotechnology research research
expendit. expenditures
1980 77 ,417 831 161, 562 13,616 50,898 131
1981 80,993( 711(18. 176,394( 15,912(16. 56,570(11. 090(23.
1982 90,063(11. 860(20. 193, 046 (10. 19, 113(20. 212( 123(20.
Fiscal Total
Year research
expendit . Food Others
Biotechnology Total Biotechnology research research research
expenditures expendit. expenditures
All Industries (Total) Total Biotechnology research research
expendit. expenditures
1980 27, 734 979 308, 351 502 625,962 33. 059
1981 32,668(17. 318(33. 346,737(12. 873(10. 693, 362 (10. 39,904(20.
1982 38, 352(17. 11. 920(27. 390,795(12. 807 773,468(11. 47,823(19.
Note: 1. These figures represent tabulation of replies from 112 firms.
(medical drug 12, chemical 47, textile, paper & Pulp 9, food 22 and other
industries 22).
2. Figures in ( ) show increases over the preceeding fiscal year.15-
R & D RESPONSES : MEMBER STATES OF THE EUROPEAN COMMUNITY
The following sections give fuller details of activities and R & D
policies relating to Biotechnology, in the Member States of the
Community. Although inevitably brief and Uneven, being summarised
from heterogenous source materials, these descriptions indicate the
common perceptions and needs, and hence provide a background tor the
discussion of European Community activities and policy for R & D in
biotechnology.
A final section, 2. 10, summarises the statistical picture with
estimates of total expenditure on R 6. D in biotechnology and related
areas.
Federal Republic of Germany
Germany has for many years had outstanding industrial strength in
all major areas of biotechnology. Initiatives by DECHEMA (Deutsche
Gesellschaft fur Chemisches Apparatewesen) led to a major report in
1974 on the significance of biotechnology, and a revised version was
subsequently commissioned by the Bundes Ministerium fur Forschung
und Technologie (BMFT) .
B~1FT has summarised in ilLeistungsplan 04" a clear picture of federal
expenditure on R & D in biotechnology : Figure 1 is based on the
plan as at January 1980, showing the breakdown of the planned
expenditure of DM 53 m. on proj ect expenditures. To this should be
added some DM 17 m. for support of biotechnology at the Gesellschaft
fUr Biotechnologische Forschung and other institutions. Planned
proj ect expenditures for 1983 : DM 63m. (increase : 14. 5 %) . Figure
2 shows the historic growth.
The BMFT also makes extensive uSe of collaborative agreements in
research with many other countries, including Japan, Sweden, and
Canada as well as with EC partners.
.,.
Biotechnologie : Studie Uber Forschung und Entwicklung : Moglichkeiten,
Aufgaben und Schwerpunkte der Forderung, DECHEMA, 1976.16-
The maj or strengths of German biotechnology lie in its large
chemical and pharmaceutical companies : BASF,. Bayer, Boehringer
Mannheim. Boehringer Ingelheim, Degussa (amino acids), Roechst,
Merck, Schering. There is close collaboration with educational
institutions, and with the industrially-oriented activities on the
GBF and DECHEMA.
Hoechst is the largest of the chemical/pharmaceutical companies. and
attracted considerable comment when in 1981 it signed a 10-year,
$ 67 m. research agreement with Massachusetts General Hospital for
work on molecular biology and genetics. This should be seen in the
context of the company s total pharmaceuticals R & D budget of some
$ 270 m. p.a. With BMFT support, Hoechst has developed a
single-cell protein now being tested for human nutrition (production
scale 2000 t. p. a.
) .
Chemical Engineering (12 July 1982) quotes an estimate that "West
German firms will boost their biotechnology R &D outlays from the
current (estimated) $ 90 million/year to nearly $ 200 million by
1985"
There is additional expenditure on biotechnology through local
government , often in collaboration with industry. The
Baden-WUrttemberg regional government has, for example, approved DM
30 m. for the construction of a new molecular genetics institute .
Heidelberg, which will be supported also by the BMFT (DM 13 m. over
3 years) and by BASF (DM 4 m. over 5 years). A similar project in
Berlin is being jointly financed (DM 40 m. each over 10 years) by
Schering AG and the city.
(3)O
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Figure 2 :  growth of expenditure on biotechnology R & D in FRG, 1974-1983.
I!ZZlJ Proj ect expenditures
Institutional support
Gesellschaft fUr Biotechnolologische Forschung
Gesellschaft fUr Strahlen und Umweltforschung
Kernforschungsanlage. JUlichQI 
France
The President of the Republic commissioned from Professors Gros,
Jacob and Royer a major study, "Sciences de la Vie et Societe"
whose publication in October 1979 is a convenient starting point for
the consideration of public policy towards biotechnology . This
report was very "European , emphasizing that the diversity and
complexity of advanced teaching and biological research have become
such that a sufficiently large and competent group can be organized
only on a European rather than a national basis. Concerning the
basic tools of biological research - measuring devices, biological
materials, buildings, databanks and stocks of living materials,
France is seen as excessively dependent on foreign sources ; but
with adequate investment, the authors believe that French industry
should be able to correct the situation within 10 years.
Parallel to the Gros, Jacob and Royer report, Joel de Rosnay
produced an informative document giving details of French and
foreign capabilities in each area of biotechnology.
A briefer and more succinct, policy-oriented report was requested by
the Prime Minister, and J. C. Pelissolo was charged with this
***
responsibility. His report considers in turn public sector
research, industry and the controlling administrations. It aims to
identify strengths and weaknesses, and identify the principal
problems to be solved to ensure industrial success.
Public sector research is seen as of good quality, but its transfer
to, and exploitation by, industry is restricted by inflexibilities.
Pelissolo sees French industry as backward in biotechnology, behind
not only the U. S. and Japan, but also Germany, the Netherlands and
Britain. There is insufficient knowledge in the leading industrial
teams. He considers several specific fields in detail
Health : strong in pharmaceuticals (Rhone-Poulenc, Roussel
Uclaf), but a maj or deficit in antibiotics ; strong in
immunology.
***
Documentation Francaise
Biotechnologies et Bio-Industrie , Joel de Rosnay, Documentation
Francaise, 1979.
La Biotechnologie. Demain 1" . Jean-ClaudePelissolo, rapport a. M.
le Premier Ministre, Documentation Francaise, December 1980.- 20-
Agriculture : risks of external dominance of the .seed industry
need to exploit INRA genetics research and  in vitro plant
propagation know-how.
Agro-food : traditional brewing and cheese-making lacks research
and innovative strength; more active are the food- and
feed-additive industries, with 10-50 % (depending on product) of
world amino acid production (70-80 % exported), and a major
converter of maize (1. 3 m. tonnes of maize processed into 300
different products). TheEEC iso-glucose regulations are seen as
damaging, benefitting only the Japanese and still more the
American producers in the long term.
Chemicals : biotechnological applications currently modest, but
expected to increase : French industrial interest lagging behind
American and German activity.
Pelissolo set as first obj ective the increase of France 
1 s research
potential. and of its utilization by industry. High quality
fundamental research must continue to be financed by the state.
France must make good from foreign sources what she cannot find at
home, buying foreign firms, and promoting academic and industrial
exchanges of research fellows with the best foreign laboratories.
Amongst his many specific recommendations, Pelissolo included the
creation of a  Mission for Biotechnology , to orchestrate and
stimulate national competence in the field.
The subsequent change of administration in France reinforced the
strong pub lic commitment to biotechnological development.
coordination being focussed by the creation of the "Mission
Biotechnologie , under Professor Pierre Douzou.
This had a budget of some FF 70 m. (10 m. Ecu) to spend on research,
but as its Director has pointed out, funds from other national
agencies (such as the Agence Nationale de Valorisation de
Recherches : ANVAR) could double or treble this amount. The research
Ministry s neW strategy involves the creation of four technology
transfer centres for biotechnology : Compiegne, Toulouse and two in
Paris : Institut Pasteur and an expanded INRA fermentation centre,
at Grignon. At these, scientists will be encouraged to work in
collaborative "cells" with engineers and technologists from local
companies. Also planned are some 60-80 fellowships to encourage21 
scientists in universities and in industry to do applied research
and/or update their knowledge.
Total expenditure by the French government was estimated to have
been some FF 200m. (29 m. Ecu) on education and research in
biotechnology.
The Mission Biotechno1ogie completed its work at the end of 1982
with the production of a "Mobilisation Programme" for promotion of
biotechnology, advocating for the first 3 years of the 10 year
programme a total budget of FF 690 m. (1982 francs), i. . FF. 230 m.
a. (36 m. Ecu), for the Ministry .of Industry and Research 1 s
agencies DESTI and ANVAR; and advocating related budget increases
for key national research agencies (CNRS, INSERM, INRA) and
institutions (particularly Institut Pasteur) . Many of the projects
also depend upon inter-ministerial co-operation, with Agriculture.
Education and Health.
Following the currency realignments of March 1983 and subsequent
economic measures, a number of the planned budgets have had to be
reduced, including in particular that of the Mobi1isation Programme.
Italy
The Italian government s support for life sciences and biotechnology
research is channelled mainly through the Council for National
Research (CNR). The CNR has announced a Task Programme on Genetic
Engineering, to run 1983- 1987, with a financial commitment of the
order of 15 m. Ecu over the 5 years (i. e. some 3 m. p.
The proj ects relating to human health are grouped in a programme on
Genetic Engineering and Molecular Bases of Hereditary Disease
comprising 3 sub-programmes:
1) Genetic engineering,
2) Cellular Biotechnology,
3) Molecular Bases of Hereditary Diseases.
Financial commitment for the first year is (in M. Lire) 880 for 1),
420 for 2), and 1100 for 3, total 2400. Mention should also be made
of the CNR Task Programme on "Increase of Agricultural Resources
Productivity , covering several research projects involving genetic
engineering relevant to agriculture.
Ministere de la Recherche et de l' Industrie : Mission des
Biotechnologies
: "
Programme mobi1isateur : l' essor des
Biotechno10gies , 1982.~ 22 
There has also been reported (Scrip, 26 July 1982) a plan to spend
$. 91 m. on biotechnology over the next 5 years, over half of this
from government and the rest from private industry. The intention is
to draw extensively upon the experience gained in CNR' s biomedical
technology research programme (say 10 m. p. a. ; 10 + 3 = 13 m. Ecus
Other public sector initiatives include support for biomass energy
project.s, and generous financial support for the installation of
anaerobic digesters to cope with the effluent problems of intensive
animal units.
Of special interest is the recent agreement between FIAT (Soria),
ENI (SClavo) and MONTEDISON (Carlo Erbe-Famitalia) for common
precompetitive research in the field of monoclonal antibodies for
diagnostic methods and developments. Financing of this project
(1983-1987) has been approved by the government amounting to 5 
Ecu, through an IMI contract (via Tecnobiomedica).
CNR also supports a number of research institutes of major relevance
to biotechnology: such as the Institute of Genetics and Biophysics
in Naples, the Institute for Germp1asm in Bari, the Institute of
Cell Biology in Rome, and the Institute of Mutagenesis and
Differentiation in Pisa. It also supports several centres located in
universities such as the Centre for Nucleic Acids and the Centre for
Molecular Biology in Rome.
Turning to industrial research, mention should be made of the
advanced work in immobi1ised enzymes for detoxification,
particularly within FIAT (Sorin) and ENI (SNAM progetti).
Italy has developed a substantial fermentation industry for
pharmaceuticals, citric acid and single cell protein.
The Netherlands
An extensive review of both biotechnology and of Dutch national
capability was published in April 1981 by SIT, and some key points
from this are summarized below. A government-sponsored committee was
set up in May 1981, under the chairmanship of Professor Schilperoort
of the University of Leiden, with the aim of coordinating research
on the Netherlands and increasing its emphasis on commercial
Biotechnology: A Dutch perspective , ed. J . F. van Ape1doorn 
Stichting Toekomstbeeld der Techniek (Netherlands Study Centre for
Technology Trends).23 ~
applications. The Committee includes experts from industry,
universities, and the governmental applied research organisation
TNO. Four million florins a year has been made available for the
biotechnology committee to allocate to selected projects.
The committee reported in April 1982, and has emphasized not the
creation of new centres for biotechnology, but the strengthening of
cooperation between government institutes. universities and
industry. It urges the government to provide extra support to
stimulate innovation in biotechnology - at least an extra 75 m.
florins (28 mua) over the period 1982-1988 - drawing on the
government s fund for industrial innovation.
The Committee emphasizes applied research in areas of existing
strengths of Dutch companies - agriculture, dairy industries,
fermentation and antibiotics ; and for future research, the
development of host-vector systems, somatic cell hybridation, second
generation enzyme reactors, and downstream processing technology.
The Committee, echoing widespread earlier calls from industry,
universities. and the STT report, recommends bringing the Dutch
regulations on DNA experiments into line with the less strict
criteria adopted elsewhere , and harmonized on a single national,
rather than municipal, basis.
Professor Schilperoort Sees the need to improve internal
communication structures .: Dutch industry and universities often
have extensive contacts abroad at the expense of national
collaboration. The country has a large fermentation industry, in
many respects of international standard. Research facilities outside
industry are very limited, reducing the potential for international
competitiveness. In the food ind~stry, Dutch breweries and dairy
plants are sophisticated and internationally competitive.
The Netherlands has an excellent tradition of microbiology,
biochemistry and process engineering, and has a leading
international position in effluent treatment, developed in response
to the needs of the food industries.2..
- 24-
The company Gist-Brocades is Europe s maj or producer of penicillin,
with corresponding expertise in fermentation technology. It is also
one of the world' s major producers of enzymes, and is carrying out
intensive $tudy on their production, isolation and application, on
laboratory and commercial scale. Related research is under way at
the universities of Delft and Wageningen ; detail$ .of the$e and
other univer$ity research centres .are given in the STT report. In a
paper on education for biotechnology in the Netherland$, it is
estimated that re$earch expenditure in the universities amounts to
19.3 m. Dfl p. a. (7. 6 m. Ecu).
Denmark
Biotechnology is critical for Denmark. The agricultural (24 %), food
(34 %) and chemical (10 %) industrie$ together dominate the
manufacturing" economy. Everyone has heard of the Carlsberg
brewery, with its traditional skills in brewing, which have
supported the creation of an international research centre with
outstanding competence in plant genetics and cell biology. Everyone
has also heard of Novo, which dominates the world market in.
industrial enzymes. Novo practised biotechnology before the word was
invented, and is now arguably the world' s leading company in the
field.
Denmark spends about 700 m. Kroner annually (86 m. Ecu, private and
public sector) on biotechnology research, somewhat less than 1 % of
product value, but heavily biased towards the chemical sector (Novo
contributes 200 m. of this). It is now being argued by some that
research investment in agriculture and food should be increased.
In 1978 the Danish Technical Research Council, under the
chairmanship of Prof. O.B. Jorgensen, took the first initiative in
the field and supported proj ects in genetic engineering scale-up
problems (with particular reference to genetic stability), product
recovery (with special reference to selective recovery of
intracellular products) and on protein synthesis. More recently, a
Ministry of Industry "initiative group" recommended against creating
a new institute specially for biotechnology because the subject was
of such widespread interest that it needed to be practised widely.
In April 1981, another Ministry of Industry initiative group" was
formed under the chairmanship of Prof. Ulrik V. Lassen, research
manager of Novo, to consider applied genetic engineering in Denmark.--- 25 ---
It reported in Novemb.er 1981 and recoIIUIlended that individual research
proposals should be supported and that appropriate guidelines or rules to
govern applied research and industrial use of genetically manipulated
micro-organisms should be developed. Its principal recommendation was that
a Working Group to study the genetic manipulation of microorganisms should
be set up at the Technical University, with a view to the appointment of a
Professor at a later date. This working group was started in October 1982
and now comprises 4 scientists and 3 technicians. It will aim to provide a
microbial genetics service to industry.
Denmark is developing a unique biotechnology, based on a unique
biotechnology company; with cooperation from government and
university.
The United Kingdom
6. 1.  Government policy and Research Council ac tivi ty
A major report on biotechnology was published in April 1980 by a
Joint Working Party drawn from the Cabinet' s Advisory Council for
Applied Research and Development, the Advisory Board for the
Research Councils and the Royal Society. This report is usu'ally
known as the Spinks Report after the Chairman of the Working Party,
Alfred Spinks, formerly Director of research at lCI.
Seeing large potential growth in the field, both for existing
industries and new .ones, the report recommended a policy of
technology push" reflected in a firm coIIUIlitment to strategic
applied research, and funded by Government intervention. Detailed
recommendations were that Research Councils should spend at least
E 3 m. (5 m. Eu) annually on biotechnology research, and that the
Government should spend about E 2. 5 m. a year (including existing
projects) in a coherent prograIIUIle of industrial R Eo D to involve
industry, Government research establishments, universities and
research associations. A further specific recommendation was for the
establishment of a research-oriented biotechnology company
(suggested cost E 2 m.- 26-
The initial response of the Government, in a White Paper on the
subject, was strongly to emphasise the role of market forces and the
private sector, to exploit British scientific and technical
discovery and build up its competitive position by importing good
developments through licences or otherwise as well as from its own
research and development.
Initially at least this attitude, and the lack of specific policy on
the vital area of education for biotechnology, were seen as clearly
differentiating the Government s attitude from that of France, West
Germany and Japan.
Subsequently however, many aspects of the Spinks report have been
implemented, illustrated by the following developments
the Research Councils noW spend more than f. 7 m. between them on
narrowly defined biotechnology. and a coordinating committee has
been set up ; indeed their evidence to the Parliamentary
Committee currently investigating biotechnology gave the figures
shown in Table 2, suggesting a possible total exceeding f. 25 m.
(43 m. Ecu). mainly attributable to the medical "underpinning
research.~ 27-
TABLE 2 : U. K. Research Councils annual expenditure On biotechnology (Em)
Agricultural Research Council (total 1982/83 budget about E92 m.p.
. genetic manipulation (primarily of plants = 1.
. other areas of biotechnology including veterinary,
vaccines and monoclonal antibodies etc for
veterinary diagnostics
. related "under-pinning" research = of the same order
Total about f. 5 m.
Medical Research Council (total budget about EI07 m.
. ona rigorous definition (research directed
specifically to the development of something with
a foreseeable commercial end such as a vaccine or
diagnostic reagent) ~ of the order of
. conceptual underpinning ~ molecular biology,
molecular genetics approximately 10" (verbal
answer) ; underpinning research (e. g. in the
chemistry, organisation and function of genes) =
the Council spent  E 17 million in 1980-81"
(written submission)
p.a.
Total 18.
Science and Engineering Research Council
. current annual expenditure on biotechnology
research (divided roughly into two-thirds for basic
biological research and one-third for engineering
research) = E 1 million, including DNA, aspects of
microbiology and molecular genetics, immobilised
enzyme and cell systems, fermentation including
downstream processing, waste treatment and the
leaching of metals from ores. Planned to increase
to E 2. 5 million by 1985/86
Total
Natural Environment Research Council
Present role relatively minor (EO.6 million p.
but many interactions and areas of research activity
of relevance
. management of biomass production (seaweed, organic
wastes, woodlands, algae, fish)
. selection, sterile culture and propagation of tree
clones
Total
. pest control
. ecology, physiology, biochemistry and genetics of
micro-organisms (soil and aquatic)
. taxonomy. culture technology and collections
For the 4 councils 25.
Source : Minutes of Evidence of the House of Commons Education. Science and
Arts Committee, Session 1981-82, "Biotechnology" : 21 April and 10 May
1982.- 28-
a special Biotechnology Directorate has been established within the
Science and Engineering Research Council to coordinate SERC grants
for research in the field and encourage British scientists to take
up research in related areas.
a coordinating committee between Government departments has been set
up, and a number of senior industrial executives have been seconded
to form a "think ta.nk" to ~dentifybiotechnology opportunities.
Department of Industry support for R & D is now at least at the
level recommended in the Spinks report (f,2. 5 m. ) and support for
industrial investment in the area is around f, 15 m., a further
f, 16m. industrial support programme was announced in December 1982.
the University Grants Committee has been given increased funds of
f, 1 m. per annum to finance 20 extra teaching posts and research (a
recent Royal Society report estimated that over the next 10 years,
Britainwou1d require 1000 extra graduates and 4000 technicians
trained in biotechnology; an assessment which has been accepted by
the government as a basis for planning) 
a research-oriented company, Ce11tech. has been launched, its f, 12
m. capital being 44 % public (via the British Technology Group),
56 % private (Prudential Assurance. Midland Bank, British
Commonwealth Shipping, Technical Development Capital). Ce11tech has
a special responsibility for commercia1ising useful discoveries from
Medical Research Council supported laboratories; plans are also
well-advanced for the launch of a corresponding company to exploit
the results of work financed by the Agricultural Research Council,
provisionally (May ' 83) known as "Agricultural Genetics Company
Private funding (possibly Ultramar and Advent Technology) is
expected to contribute about two thirds of expected initial
financing of f, 15 m., the remainder from British Technology Group.
2.  Industrial activity
Whilst the United Kingdom s academic strength in the field of
biotechnology rests on the large number of University departments in
the life sciences. many associated with research units dependent on
the Research Councils, its commercial strength is based on large 2nd
successful companies in chemicals, pharmaceuticals and food
processing. whose research and production facilities, like those of~ 29-
some important subsidiaries of non UK firms (e.g. G.D. Searle), are
based in the UK. Imperial Chemical Industries Ltd. has played a
major role in the development of biotechnology in Britain, in fields
as diverse as plant protection chemicals (esp. pyrethroids) sewage
treatment (e. g. the deepshaft process for recycling, on limited land
space, water contaminated by organic effluents) and single cell
protein. The last has been widely publicised, with the bringing on
stream early in 1981 of the "pruteen" plant producing 60. 000 tons of
single cell protein rich in the essential amino acid lysine. Based
on a feedstock of methanol. produced from North Sea gas, this
product competes with soya and other protein sources. It has also
had to overcome the regu1aroty hurdles faced by any novel feedstuff.
The project itself is of great significance as a prototype for
large-scale biotechnology and the development of the related process
engineering. Attempts to improve the energy efficiency of the
micro-organism have included the use of genetic engineering to
produce a manipulated variant. Others strong in the field of
biotechnology include innovative pharmaceutical firms such as G1axo
and Beechams. Groups such as ICI, Shell and BP have significant
research and production capabilities in pharmaceuticals and
agricultural chemicals. Maj or food firms and brewing groups in the
UK are also showing active interest in biotechnology, ego Rank Hovis
McDouga11s fungal single cell protein and Grand Metropolitan Hotels
investment in Biogen (the only European shareholder).
Unilever s expertise at all stages of vegetable oil production (palm
tree cloning) and manipulation (inter-esterification, e.g. to
convert palm-oil mid-fraction to the equivalent of cocoa butter fat)
is another strong point of Ang1eDutch biotechnology: the examples
cited indicate also the Third World implications.
Belgium
Belgium has a strong chemical industry, and outstanding strengths in
its universities and research institutes in the biomedical sector
(e.g. the Institute for Cellular and Molecular Pathology) and in
p1ant genetics (University of Ghent), as well as in other areas
(e.g. bacteriology in various institutions). The international
pharmaceutical companies are also attracted by the high quality
environment provided by the research teams in the various
universities of the country. The rather open economy and the
presence of numerous multinational companies (chemicals,- 30-
pharmaceuticals, foods) create the problem for the public
authorities of balancing the advantages of attracting foreign
investment against the drawbacks of a potential internal
braindrain" into these companies, with insufficient spin-off
benefits to the local economy.
At the level of the regional authorities, Wa1lonie, Flanders and
Brussels are seeking to attract foreign investment in high
technology sectors such as biotechnology. Hybritech (the U. S. leader
in hybridoma technology and marketing) has .estab1ished a plant at
Liege; Biogen (the Swiss and U. based group owned by Monsanto,
International Nickel. Schering-P10ugh and Grand Metropolitan Hotels)
is to establish a subsidiary at Ghent (Biogent). At the level of the
national authorities, the IRSIA - a national industrial research
association - is coordinating R & D proj ects on biotechnology topics
(e. g. on vectors, yeasts. plant tissue culture) at Belgian research
centres, and funded by 14 Belgian companies (2 year budget, some
BF 200 m).
The SPPS (National Science Policy Department) has been supporting
centres of excellence in molecular biology. through "Concerted
Research Actions" for the last 10 years (yearly budget 200 MFB).
In addition, the organization of coordinated national collections of
micro-organisms has been started, with fungi at Louvain-la-Neuve.
and bacteria at Ghent (based on substantial existing collections).
Ireland
Ireland, like Belgium, is vigorously seeking to attract foreign
investment, to take advantage from its developed educational system,
and to stimulate greater exploitation of the country 
1 s
under-uti1ised agricultural potential.
The 1981 report by the National Board for Science and Technology,
Biotechnology Trends" emphasised chemicals, pharmaceuticals,
health-care and food processing as sectors within which there are
processes and products of special potential significance. The
possibility of gaining technology transfer from innovative U.
companies is noted. A maj or national policy document is planned to
appear by mid-1983. outlining a development plan for Irish
biotechnology ; focussing on industrial, research and educational
policy and their integration.- 31-
Greece
The Ministry of Coordination, in consultation with the Ministries of
Science and Technology, Education and Agriculture, is currently
developing plans to stimulate awareness, education and application
of biotechnology, in the cOntext of the 1983-88 5-year plan for
economic and social development. This includes a programme for
scientific and technological development, .an element of which
concerns "key technologies" : containing three themes
a) microelectronics and informatics
b) biotechnology
c) technologies relating to marine exploitation.
This choice reflects top-level political decisions, and ambitious
plans are now being implemented to create the necessary foundations.
A key potential asset are the many highly-qualified Greek scientists
working abroad, a survey of whom has identified many willing to
return if suitable posts and facilities are available (e.g.
Professor Kafatos of Harvard will establish the life sciences
institute at the University of Crete).
Biotechnology and life sl~iences research is also being vigorously
promoted at several other universities (Athens. Patras,
Thessalonika) and at research centres such as the National Hellenic
Research Foundation, the Cancer Research Centre (Salonika), and NRC
Demokritos (Athens).
Professor Stavropoulos, associated with the science-based
biotechnology company Viory1 (food additives, preservatives,
flavourings, plant nutrients), is working with the government
planners to identify new industrial opportunities in biotechnology.
Plans are now well advanced for the launching of a national company,
Bio-Hel1as , which would work in close association with the
research centres mentioned.
10. Comparative National Expenditure Statistics on R & D
Reference has been made to the inter-disciplinary character of
biotechnology and to its diverse fields of application. These make
it particularly difficult as yet to obtain a clear and comparable
quantitative picture of biotechnology R & D activity in the member- 32-
states of the Community. In particular, the subject cuts across four
of the "NABS" categories (Nomenclature -for the analysis and
comparison of science programmes and Budgets) customarily used in
European Community R & D expenditure statistics:
3. Protection and improvement of  human health
5.  Agricultural productivity and technology
6.  Industrial productivity and technology
10. General promotion of knowledge
A more detailed analysis of the 1981 figures is available, and Table
3 shows expenditure by country on 12 areas more closely related to
biotechnology; the expenditure on  biosciences is most likely to be
correlated with strength in at least the foundation disciplines of
biotechnology, but there are problems of comparability caused by the
mapping of different national systems into the NABS categories. The
K. figures appear to under-represent the country s degree of
activity as compared with France and Germany. The total under
biosciences, 292. 3 m.Ecu (385. 3 m. Ecu in 1980), may perhaps be set
against the figure quoted by Rogers for Japanese government
expenditure for life sciences in general : 50 bn Yen, Le. 195 m.
Ecu.
Combining chapters 31 (Medical research: 526. 5 m. Ecu), 103
(Medical sciences : 1091. 2 m. Ecu) and 1013 (Biosciences : 292. 3 m.
Ecu) gives a figure for the EC of 1. 9 bn. Ecu in 1981 ; the 1982
outlays of the U. S. National Institutes of Health were $ 3. 4 bn.
As a rough estimate of "biotechnology-relevant" research in the
European Community, one can simply total the relevant expenditure
headings of Table 2, update (say by 10 %) for inflation to 1982, and
assume (as with the U. S. medical and agricultural figures
previously) that 10 % of this total may be described as
biotechnology-relevant . This gives an estimate of some 350 m. Ecus
($ 380 m.) for the countries listed.
Summarising the figures presented in the text, and applying to the
figures of Table 3, the above "broad basis" estimate of
biotechnology-relevant" research expenditure, gives the estimates
presented in Table 4.
A meeting of the Statistics Sub-committee of CREST will give
particular attention to the problems posed by IIbiotechno1ogy" at a
meeting in the latter half of 1983.T
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TABLE 4
SUMMARY ESTIMATES BY COUNTRY OF PUBLIC EXPENDITURE ON BIOTECHNOLOGY R & D
R. GERMANY  (BMFT) : DM 63 m. (proj ect~
plus 20 m. (in$titutional
$upport) ~ DM 83 m. 
Alternatively, estimate 10 %
of medical, agro-food and
life-sciences re$earch as
biotechnology relevant
i. e. "broad basis
" :
FRANCE: FF. 200 m. on education and research
in biotechnology in 1982 
Alternatively, "broad basis
" :
UNITED KINGDOM: L 28. 8 m. (Research
Councils, UGC, Dept. of
Industry) :
Alternatively, "broad basis
ITALY : CNR 5-year programmes on genetic
engineering and biomedical/industry
programme
Alternatively, "broad basis
NETHERLANDS : Schilperoort recommendation
of Hfl. 75 m. (' 82- 88) plus
university research 10-20 HfL
a. (Bruin) : say Hfl. 26 m.
a. :
Alternatively. "broad basis
" :
BELGIUM: SPPS (molec. bioi. etc. :
FB 200 m. p. ) plus IRSIA (100) 
at least FB 300 m. p. a. :
Alternatively, "broad basis
" :
DENMARK, GREECE. IRELAND , LUXEMBOURG : say
(M.  ECUS - 1982/1983)
Biotechnology-
Biotechnology relevant
146
-------- --------
(U. s.  m. : 156
132
355
------- -------
378)